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credible interval: 1.4 to 14.8). Results of synthesizing IPD using information on a
covariate account for possible ecological bias and show a clear improvement in
accuracy over estimated treatment-covariate interactions, when compared to re-
sults obtained from synthesizing AD. CONCLUSIONS: Including evidence at IPD
level in the MTC is advisable when exploring participant level covariates; even
when IPD are only available for a fraction of the studies forming the evidence base.
Our findings suggest that adjusting for covariates impact produces intervention
effect estimates of higher accuracy, which is valuable for estimating subgroup
effects or adjusting for inconsistency.
PODIUM SESSION II:
DISCUSSION ON DECISIONS AND THE IMPACT OF NICE AND OTHER
REGULATORY BODIES IN THE UK
NI1
THE UK NICE SINGLE TECHNOLOGY APPRAISAL PROCESS: A QUALITATIVE
STUDY BASED ON MANUFACTURERS’ SUBMISSIONS
Kaltenthaler E
University of Sheffield, Sheffield, UK
OBJECTIVES: International health technology assessment is increasingly inter-
ested in the rapid review of technologies. In the UK NICE Single Technology Ap-
praisal (STA) process, manufacturers present the clinical and cost effectiveness of
new technologies in their evidence submissions. These submissions are critically
appraised by Evidence Review Groups (ERGs) who produce a report which forms
part of the evidence considered by the Appraisal Committees. Early on in the pro-
cess the ERG requests more information from the manufacturer via a clarification
letter. The purpose of this research was to analyse ERG reports and clarification
letters in order to develop guidance for manufacturers based on common problems
or issues identified in manufacturer submissions (MS). METHODS: A thematic
analysis of the first 30 completed ERG reports was undertaken using a framework
approach. Twenty one of the available associated clarification letters were anal-
ysed using a set of open codes to analyse data. Both sources of evidence were used
to identify common issues and concerns. RESULTS: Inadequate reporting of pro-
cesses was identified in 90% of reports; criticisms of data used, especially in the
model was mentioned for 67% of the reports and issues with the conduct of the
systematic review in 57%. The population and comparator represented the key
items in the decision problem assessed by the ERGs as being inadequately ad-
dressed by manufacturers. The majority of clarification points related to the eco-
nomic data analysis. Issues identified included clarification of data sources and
selection, queries about modelling decisions and requests for additional analyses.
Internal inconsistencies between the clinical and economic sections of the MS and
inconsistencies within the economic section of the MS were also identified as
particular problems. This analysis was used as the basis for the development of 12
recommendations for manufacturers. CONCLUSIONS: These recommendations
may help to improve the quality of manufacturers’ submissions.
NI2
THE IMPACT OF NICE GUIDANCE ON THE DIFFUSION OF MEDICAL DEVICES
Cabo R1, Sorenson C2, Lynch P3, Eggington S4
1GE Healthcare, Bucks, England, UK, 2London School of Economics and European Health
Technology Institute for Socio-Economic Research, London, UK, UK, 3Medtronic, Tolochenaz,
Switzerland, 4Medtronic International, Tolochenaz, Vaud, Switzerland
OBJECTIVES: Health technology assessments (HTAs) have the potential to influ-
ence the diffusion of medical devices into health care systems. This study investi-
gates the impact the National Institute for Health and Clinical Excellence’s (NICE)
technology appraisals have on the diffusion of implantable devices in the UK (UK).
METHODS: The analysis focused on the impact of NICE guidance on volume sold of
three medical devices: drug eluting stents (DES), implantable cardioverter defibril-
lators (ICD), and spinal cord stimulators (SCS). UK sales data (2005-2010) for each
device were collected from Eucomed and other industry sources. Diffusion pat-
terns before and after publication of NICE guidance were analyzed from an aggre-
gated market-level perspective. A linear regression model was fit to the time series
data to illustrate the relationship between the NICE decision and volume.
RESULTS: The results from the statistical analysis show that NICE guidance has
different effects on diffusion across products. NICE guidance had a step increase
impact in adoption of DES and SCS (p0.026 and p0.00, respectively).The model
suggests that the NICE review did not predict the diffusion of ICDs. Descriptive
analysis demonstrated that for SCS and ICDS the NICE decision had a positive effect
and no impact on DES diffusion on volume over time. Overall the units sold were
positively and significantly correlated with time post-NICE guidance.
CONCLUSIONS: The study indicates that NICE guidance influences the adoption of
medical devices. Positive recommendations were associated with an increase in
units sold despite a decrease in units sold experienced before the final recommen-
dation. Additionally, the analysis suggests that there may be a lag between a pos-
itive NICE decision and adoption of guidance recommendations in practice. Lastly,
there were no consistent trends on NICE’s effect on the rate of diffusion. More
research is needed to clearly understand the dynamics of HTAs on technology
adoption.
NI3
ECONOMIC EVALUATION IN NICHE MARKETS: THE ROLE OF THE UK’S
ADVISORY GROUP FOR NATIONAL SPECIALISED SERVICES FOR RARE DISEASES
AND DISORDERS
Khan N1, Kiss N1, Pang F2
1Oxford Outcomes Ltd., Morristown, NJ, USA, 2Shire Human Genetic Therapies, Inc, Basingstoke,
UK
OBJECTIVES: The Advisory Group for National Specialised Services (AGNSS) is a
new committee that advises health ministers on which orphan services, including
orphan drugs, should be nationally commissioned. The aim of this paper is to
provide a description of AGNSS priorities, budget, and synergies with the National
Institute for Health and Clinical Excellence (NICE), and an analysis of the decision-
making framework used by AGNSS to recommend new drugs and technologies.
METHODS:A web-based search was conducted for articles and information related
to the specialized services of the National Health Service (NHS) and NICE. All doc-
uments, including AGNSS meeting minutes were analyzed to provide a compre-
hensive understanding of the AGNSS program. RESULTS: Beginning in 2010 and
each year thereafter, AGNSS will recommend approximately 60 highly specialized
services and a small number of new drugs and technologies that affect fewer than
500 patients in England. Drugs and stand-alone technologies first must be submit-
ted to NICE. Based on prevalence, disease severity, resource impact, and clinical
benefit, a subset of these are referred to AGNSS for consideration. AGNSS can
recommend “accept” or “accept with conditions” when the application meets the
quality, innovation, productivity, and prevention criteria, or will recommend to
“defer” or “reject” otherwise. Currently, AGNSS has identified eight priority areas
for 2011-2012. The total program budget in 2010/11, excluding three high-cost drugs
categories, is expected to be about £348 millions. Additionally, the planned budget
for high-cost drugs such as enzyme replacement therapy, paroxysymal nocturnal
hemoglobinuria (PNH), and cryopyrin-associated periodic syndromes (CAPS) is
£128,879, £27,592, and £3,080 million, respectively. CONCLUSIONS: Under the cur-
rent NHS framework, access to orphan drugs can be denied if they surpass NICE
implicit willingness to pay thresholds. The introduction of AGNSS offers an alter-
native evaluation mechanism, one that potentially offers the flexibility necessary
to comprehensively review orphan drugs and services.
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THE ASSOCIATION BETWEEN FINANCIAL IMPACT AND THE LIKELIHOOD OF
RECOMMENDATION OF MEDICINES FOR USE IN ENGLAND AND WALES
Mauskopf JA1, Chirila C1, Birt J2, Boye KS2, Bowman L2, Grainger D3
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OBJECTIVES: To estimate the relationship between the maximum possible finan-
cial impact (MPFI) of a new medicine on the UK (UK) National Health Service (NHS)
and the probability of the drug being recommended for use in England and Wales
by the National Institute for Health and Clinical Excellence (NICE).METHODS:Data
were abstracted from the NICE guidance document and costing template for deci-
sions made about drugs between January 2001 and March 2011. MPFI was calcu-
lated by multiplying the population eligible for treatment with the new drug based
on the UK marketing indication by the upper bound estimate for the annual cost of
treatment. Descriptive, logistic, and recursive partitioning decision analyses were
used to estimate the relationship between the MPFI of a new medicine and the
probability of recommendation for use with or without restrictions. Multivariable
analyses controlled for other clinical and economic variables that have been shown
to be correlated with the probability of recommendation for use, including the cost
per quality-adjusted life-year (QALY) gained.RESULTS: In all analyses, MPFI was an
important predictor of the recommendation for use, in addition to cost per QALY.
In the univariate analysis, the mean MPFI was £140 million for medicines not
recommended and £92 million and £31 million for those recommended with and
without restrictions, respectively. In the logistic analysis, the coefficient on the
MPFI variable was statistically significant. In the recursive partitioning decision
analysis, the second split of the data for classifying recommendations, after cost
per QALY, was for submissions with an MPFI above or below £130 million.
CONCLUSIONS: In England and Wales, besides cost-effectiveness ratio, MPFI on
the NHS may be an important determinant of whether a new drug is recommended
for use with or without restrictions.
PODIUM SESSION II:
MERGING PRO AND UTILITY ASSESSMENT: DOES THE GAP INDEED GET
SMALLER?
UT1
COMBINING DCE AND TTO INTO A SINGLE VALUE FUNCTION
Van Hout BA1, Oppe M2
1University of Sheffield, Sheffield, UK, 2iMTA, Rotterdam, The Netherlands
OBJECTIVES: To develop a method that enables estimation of a single value func-
tion using data from discrete choice (DC) and time trade off (TTO) questionnaires
and to analyse the informative value of an additional TTO question versus that of
an additional DC. METHODS: Separate DCE and TTO studies are designed with
varying numbers of health states (EQ-5D) to be valued. The DC states do not hold a
time dimension. An optimal Federov design is chosen for the TTO states, a Bayes-
ian approach is followed for the DC states. The base line is blocked design of 20
blocks with 10 DCE’s and 20 blocks of 5 TTO’s. Responses are simulated to both
study-types using prior expectations about answering behaviour, including 10% of
individuals who do not trade time when judging TTO states. Models are estimates
separately as well as simultaneously. For the latter all information is combined
using a likelihood approach assuming a generalised linear model underlying the
answers to the DC comparisons as well as to the TTO questions. The informative
value of adding an additional DC or TTO is measured by the average precision
surrounding the model parameters. RESULTS: While the TTO data offer sufficient
data to identify a value function, the DC data need normalizing constants. Com-
bining both approaches by estimating a single likelihood function takes care of this
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successfully but only after introducing a multiplicative scale parameter to distin-
guish between both approaches. With 1600 respondents, adding 1 TTO offers more
informative value than adding 1 DC but not as much as adding 2 DC’s.
CONCLUSIONS:The likelihood approach effectively estimates the structure under-
lying the simulated data. Given that DC is less burdensome than TTO, one may
prefer to add more DC’s than TTO’s. That is – as in this case – when the underlying
modelling assumption apply.
UT2
UPDATE OF THE PATIENT-REPORTED OUTCOME AND QUALITY OF LIFE
INSTRUMENTS DATABASE (PROQOLID) USING THE FDA GUIDANCE ON PRO
MEASURES
Caron M, Perrier LL, Vaissier V, Savre I, Acquadro C, Emory MP
MAPI Research Trust, Lyon, France
OBJECTIVES: In 2002, PROQOLID was launched to provide an overview of existing
PRO instruments and facilitate access to the instruments and their developers,
through the structured presentation of synthesized, reliable, and updated data. In
2009, the Food and Drug administration (FDA) published its final guidance on the
use of PRO measures which describes how the FDA will review PRO instruments
used to support claims in approved medical product labeling. The objectives of this
study were to review and adapt the template of PROQOLID to harmonize its struc-
ture and language with those used in the FDA guidance, acknowledging that PRO-
QOLID and the guidance have different OBJECTIVES: provision of information vs.
review of information.METHODS:Content and structure of PROQOLID and the FDA
guidance were compared. Proposed changes in terminology and structure were
submitted to a panel of PRO experts (n2). RESULTS: The information on PRO-
QOLID is divided into 12 sections. The FDA guidance categorizes information into 5
parts. Twelve changes in terminology were made across all sections. For instance,
Time recall” was changed to “Recall/Observation period”, and “Dimensions” to “Do-
mains”. Fourteen changes of structure were made, mainly in Sections 6 and 7. Section
6 (Methodology of development) was renamed “Content Validity documentation”. In
this section, the heading “Information retrieval” was replaced by “Concept elicitation
and Item generation”. “Conceptual framework” will be moved to Section 5 (Descriptive
information). Section 7 (Psychometric properties) was renamed “Measurement Prop-
erties”. Within the “Reliability” heading, a subheading on “Inter-interviewer reproduc-
ibility” was added. A new section was created: “Data analysis and Interpretation. Five
sections remained unchanged (1 to 4, and 8). CONCLUSIONS: The comparison of
PROQOLID and the FDA guidance led to numerous changes in the wording and
structure of the database. These changes will improve the functionality of PRO-
QOLID and help users to better fulfill FDA requirements.
UT3
THE VALIDITY OF THE EQ-5D, SF-6D, SF-36 AND SF-12 IN MENTAL HEALTH
CONDITIONS: A SYSTEMATIC REVIEW
Papaioannou D, Peasgood T, Brazier J, Parry G
University of Sheffield, Sheffield, UK
OBJECTIVES: To assess the validity and responsiveness of the SF-36, SF-12, SF-6D
and EQ-5D in mental health conditions. METHODS: Systematic reviews were un-
dertaken in five mental health conditions. Ten databases were searched to August
2009. Studies were appraised and data extracted. A narrative synthesis was per-
formed on construct validity including known groups validity (KGV) (ability to de-
tect differences in HRQL scores between groups), convergent validity (CV) (strength
of association between generic HRQL and other related measures (e.g. symptoms or
function) and responsiveness (R) (i.e. changes in scores in responders/non-re-
sponders to treatment and correlation with changes in related measures).
RESULTS: Within schizophrenia, the majority of evidence related to the SF-36
(n25) and EQ-5D (n9). Both measures demonstrated KGV but this was mostly
limited to demonstrating differences between individuals with schizophrenia and
the general population. Contradictory results were found in studies measuring CV
and R using clinical measures of symptom severity. For bipolar disorder, 23 studies
were identified, almost exclusively on the SF-36; which was able to detect known
differences in symptom severity and correlated strongly with clinical measures of
depression (weakly with mania measures). For personality disorders; the majority
of studies (6/9) related to the EQ-5D, which showed good KGV and R. For depression
and anxiety, 23 EQ-5D and eight SF-6D studies were identified. Both measures
demonstrated good CV and R for depression; however KGV may be driven by the
presence of co-morbid depression in patients with anxiety disorders.
CONCLUSIONS: Overall, the evidence suggests that the generic HRQL measures are
appropriate in four mental health conditions, but raises doubts about their use in
schizophrenia. Caution is required when interpreting CV evidence using clinical mea-
sures, since the lack of relationship may reflect genuine lack of difference in HRQL. More
evidence using better indicators for testing validity and responsiveness are required.
UT4
COMPARISON OF THE PERFORMANCE OF EQ-5D AND SF-6D IN PATIENTS WITH
CHRONIC PAIN –RESULTS FROM 3 RANDOMIZED CONTROLLED TRIALS
Obradovic M, Lal A, Liedgens H
Grünenthal GmbH, Aachen, Germany
OBJECTIVES: To compare EQ-5D and SF-6D utilities in patients with chronic pain
due to osteoarthritis (OA) of the knee or low back pain (LBP) derived from phase III
trials with tapentadol. METHODS: Three phase III trials with identical design in-
cluded EQ-5D and SF-36 questionnaires to measure quality of life of patients with
pain due to OA or LBP treated with tapentadol prolonged release (PR), oxycodone
controlled release (CR) or placebo. EQ-5D and SF-6D indices were obtained using
the UK weights. The ability of the two utility measurements to discriminate among
different health states was tested. RESULTS: Both SF-6D and EQ-5D utility values
increased from baseline to endpoint (15 weeks). The increase (mean of all patients
with active treatment) was substantially higher when measured with EQ-5D (0.16
vs. 0.06). The EQ-5D better distinguished among health states (different severity of
adverse events, pain relief, withdrawal rates). While utilities were very similar in a
group of patients who tolerated the treatment (0.695 and 0.694 for EQ-5D and SF-6D,
respectively), EQ-5D utilities were considerably lower in patients who withdrew
due to adverse events (0.503 and 0.597 for EQ-5D and SF-6D, respectively). A similar
pattern was seen in patients with various levels of pain relief. In patients with
30% pain relief mean EQ-5D and SF-6D utility was 0.716 and 0.708, respectively.
The EQ-5D utility in patients who withdrew due to lack of efficacy was 0.405, when
analyzing the SF-6D utility this resulted in 0.580. CONCLUSIONS: Both generic
instruments to measure quality of life, EQ-5D and SF-6D, showed that avoidance of
severe treatment-related adverse events and sufficient pain relief has a large ben-
eficial impact on patient’s wellbeing. In the clinical trials analyzed the discrimina-
tive power of the EQ-5D was stronger showing that this instrument is a useful tool
also in pain studies to analyze patient’s QoL.
PODIUM SESSION II:
DISCUSSIONS ON THE ADDED VALUE OF VALUE OF INFORMATION
VI1
DETERMINING THE IMPACT OF MODELING ADDITIONAL SOURCES OF
UNCERTAINTY IN VALUE OF INFORMATION ANALYSIS
Corro Ramos I, Rutten-van mölken MP, Al MJ
Erasmus University, Rotterdam, The Netherlands
The conditional reimbursement policy for expensive medicines in the The Nether-
lands requires real-world data collection on cost-effectiveness within a four years
period (T4) after the initial decision to reimburse a drug (T0). This introduces
new sources of uncertainty, which are less important in an RCT than in real life. This
may affect the priorities for further (real-world) research as determined in a VOI
analysis. OBJECTIVES: Identifying and modeling types of uncertainty that are usu-
ally not parameterized at T0 but may become relevant at T4. Include them in the
VOI analysis.METHODS:We use a hypothetical model with four states and param-
eters related to transition and exacerbation probabilities, costs and utilities. Three
additional uncertainties were parameterized: persistence, compliance and broad-
ening of indication. Persistence refers to the duration of the treatment and it is
determined by the probability of dropping out of the treatment. Compliance is
characterized by the fraction of the treatment benefit obtained due to not taking
the medication as it was indicated. The impact of indication broadening is modeled
as the percentage of the RCT treatment effect realized in the outcome study. These
extra parameters were included in the VOI analysis. RESULTS: Priorities change
when new uncertainties are introduced in the model. Initially, the EVPPI was high-
est for transition probabilities followed by utilities; and it was very low for exacer-
bation probabilities and costs. After new uncertainties are included, compliance
and broadening of indication (which is applied only to the new treatment) become
as relevant as utilities. Persistence however has little impact in the model.
CONCLUSIONS:VOI analysis at T0 should anticipate and parameterize new types
of uncertainty that may emerge during a four year outcomes study. This would
help to focus the real-world outcomes study on those parameters that reduce
uncertainty in the decision to continue the reimbursement most.
VI2
A NOVEL APPROACH TO ANALYSING VALUE DRIVER IMPORTANCE ACROSS
MULTIPLE TARGET PRODUCT PROFILES
Wild L1, Mukku SR2
1Double Helix Consulting, London, UK, 2Double Helix Consulting Group, London, UK
OBJECTIVES: To develop a novel semi-quantitative model to assist pharmaceutical
companies in making investment decisions, by assessing relative importance of
value drivers in a given therapy area and how this translates to perceived value of
a product profile. METHODS: Perceived value for a number of product profiles is
assessed through a semi-quantitative scoring method, followed by an in-depth
qualitative interview. In the scoring phase, respondents rate the relative impor-
tance of value drivers and provide thresholds for minimal and strong value in each
domain. Respondents assess target product profiles, scoring profile performance in
each value driver on a pre-defined scale. RESULTS: This methodology provides a
range of valuable data in understanding the drivers of value in a given therapy area.
First, the relative importance of value drivers can be used to understand which
product attributes (efficacy, safety and tolerability or administration and others)
drive product value. In addition, by providing value thresholds for each driver, we
can understand expectations, in effect defining an ‘ideal’ product scenario. Testing
product profiles against a scale calibrated by these expectations allows us to un-
derstand perceived product value in a set of likely product attributes. In addition,
by testing a number of profiles, trade-offs between different product attributes, and
the effect of these on product value, can be assessed. CONCLUSIONS: The insights
gained from this type of analysis are vital in understanding product development
priorities and the likely pricing and reimbursement potential for future products.
Multiple applications of this technique have confirmed that this is a valuable ap-
proach in supporting pharmaceutical companies to inform their clinical pro-
gramme, pricing and reimbursement strategy or commercial strategy.
VI3
SEQUENTIAL TREATMENT OF FOLLICULAR NON-HODGKIN LYMPHOMA: COST-
EFFECTIVENESS AND VALUE OF INFORMATION
Soini EJ1, Martikainen JA1, Vihervaara V2, Mustonen K2, Nousiainen T3
1ESiOR Ltd, Kuopio, Finland, 2Roche Oy, Espoo, Finland, 3Department of Medicine, University of
Eastern Finland and Kuopio University Hospital, Kuopio, Finland
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